[go: up one dir, main page]

PE20030735A1 - Derivados de benzotiazol - Google Patents

Derivados de benzotiazol

Info

Publication number
PE20030735A1
PE20030735A1 PE2002001132A PE2002001132A PE20030735A1 PE 20030735 A1 PE20030735 A1 PE 20030735A1 PE 2002001132 A PE2002001132 A PE 2002001132A PE 2002001132 A PE2002001132 A PE 2002001132A PE 20030735 A1 PE20030735 A1 PE 20030735A1
Authority
PE
Peru
Prior art keywords
benzylamide
acid
morpholin
chloro
methoxy
Prior art date
Application number
PE2002001132A
Other languages
English (en)
Inventor
Alexander Flohr
Claus Riemer
Roger David Norcross
Roland Jakob-Roetne
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20030735A1 publication Critical patent/PE20030735A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE BENZOTIAZOL DE FORMULA I DONDE R ES H, -(CH2)n-FENILO CON HALOGENO, ALQUILO, ALCOXILO, TRIFLUOROMETILO, -N(R')-C(O)-ALQUILO, -(CH2)n-PIRIDINILO, -(CH2)n-CICLOALQUILO C3-C6, -(CR'2)n-BENZO[1,3]-DIOXILILO, -(CH2)n-TETRAHIDROFURANILO, ENTRE OTROS; R' ES H, ALQUILO; n ES 0-4. SON COMPUESTOS PREFERIDOS FENETIL-AMIDA DEL ACIDO 4-METOXI-7-MORFOLIN-4-IL-BENZOTIAZOL-2-CARBOXILICO, 3-CLORO-BENCILAMIDA DEL ACIDO 4-METOXI-7-MORFOLIN-4-IL-BENZOTIAZOL-2-CARBOXILICO, 2-CLORO-BENCILAMIDA DEL ACIDO 4-METOXI-7-MORFOLIN-4-IL-BENZOTIAZOL-2-CARBOXILICO, 2-CLORO-BENCILAMIDA DEL ACIDO 4-METOXI-7-MORFOLIN-4-IL-BENZOTIAZOL-2-CARBOXILICO, 2-METOXI-BENCILAMIDA DEL ACIDO 4-METOXI-7-MORFOLIN-4-IL-BENZOTIAZOL-2-CARBOXILICO ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCESO PARA LA PREPARACION. LOS COMPUESTOS MENCIONADOS MODULAN EL RECEPTOR DE ADENOSINA A2A Y SON UTILES PARA EL TRATAMIENTO DE ALZHEIMER, PARKINSON, HUNTINGTON
PE2002001132A 2001-11-27 2002-11-25 Derivados de benzotiazol PE20030735A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01127442 2001-11-27

Publications (1)

Publication Number Publication Date
PE20030735A1 true PE20030735A1 (es) 2003-08-29

Family

ID=8179277

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001132A PE20030735A1 (es) 2001-11-27 2002-11-25 Derivados de benzotiazol

Country Status (21)

Country Link
US (1) US6596718B1 (es)
EP (1) EP1450796B1 (es)
JP (1) JP4216193B2 (es)
KR (1) KR100613197B1 (es)
CN (1) CN1325052C (es)
AR (1) AR037418A1 (es)
AT (1) ATE391505T1 (es)
AU (1) AU2002352045B2 (es)
BR (1) BR0214455A (es)
CA (1) CA2467825A1 (es)
DE (1) DE60226063T2 (es)
ES (1) ES2303558T3 (es)
GT (1) GT200200240A (es)
MX (1) MXPA04004982A (es)
PA (1) PA8558201A1 (es)
PE (1) PE20030735A1 (es)
PL (1) PL370978A1 (es)
RU (1) RU2293083C2 (es)
TW (1) TW200408391A (es)
UY (1) UY27551A1 (es)
WO (1) WO2003045385A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090286791A1 (en) * 2001-11-27 2009-11-19 Takeda Pharmaceutical Company Limited Amide Compounds
US6678828B1 (en) * 2002-07-22 2004-01-13 Vormetric, Inc. Secure network file access control system
AU2004251814B2 (en) * 2003-05-19 2009-07-23 F. Hoffmann-La Roche Ag Benzothiazole derivatives as adenosine receptor ligands
EP1669348A4 (en) * 2003-09-30 2009-03-11 Eisai R&D Man Co Ltd NEW ANTIPILIC AGENT CONTAINING A HETEROCYCLIC COMPOUND
WO2005044793A2 (en) 2003-10-31 2005-05-19 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
JPWO2005073210A1 (ja) * 2004-01-28 2007-09-06 キッセイ薬品工業株式会社 新規なベンゾフラン誘導体、それを含有する医薬組成物およびそれらの用途
US8064040B2 (en) * 2004-03-30 2011-11-22 Carl Zeiss Smt Gmbh Projection objective, projection exposure apparatus and reflective reticle for microlithography
BRPI0513510A (pt) * 2004-07-22 2008-05-06 Hoffmann La Roche benzotiazóis substituìdos
JPWO2006016548A1 (ja) * 2004-08-09 2008-05-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環化合物を含有する新規な抗マラリア剤
WO2006106711A1 (ja) 2005-03-30 2006-10-12 Eisai R & D Management Co., Ltd. ピリジン誘導体を含有する抗真菌剤
WO2006115134A1 (ja) * 2005-04-22 2006-11-02 Kissei Pharmaceutical Co., Ltd. 新規なベンゾフラン誘導体、それを含有する医薬組成物およびそれらの用途
TWI385169B (zh) * 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
US8183264B2 (en) * 2006-09-21 2012-05-22 Eisai R&D Managment Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
CN101547923A (zh) 2006-12-07 2009-09-30 弗·哈夫曼-拉罗切有限公司 作为via受体拮抗剂的螺环-哌啶衍生物
EP2097376A2 (en) 2006-12-22 2009-09-09 F. Hoffmann-Roche AG Spiro-piperidine derivatives
US7501432B2 (en) 2006-12-22 2009-03-10 Hoffman-La Roche Inc. Spiro-piperidine derivatives
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
CN102702185A (zh) * 2007-04-27 2012-10-03 卫材R&D管理有限公司 杂环取代吡啶衍生物的盐的结晶
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US8188119B2 (en) * 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
JP2014517074A (ja) 2011-06-24 2014-07-17 アムジエン・インコーポレーテツド Ｔｒｐｍ８アンタゴニストおよび治療におけるそれらの使用
EA201490152A1 (ru) 2011-06-24 2014-05-30 Эмджен Инк. Антагонисты trpm8 и их применение при лечении
WO2013042137A1 (en) * 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015143012A1 (en) 2014-03-19 2015-09-24 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2017360939B2 (en) * 2016-11-18 2022-03-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
US11639352B2 (en) 2018-09-04 2023-05-02 Hoffman-La Roche Inc. Benzothiazole compounds for the treatment of autoimmune diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8717068D0 (en) * 1987-07-20 1987-08-26 Fujisawa Pharmaceutical Co Nitric ester derivative
KR100526487B1 (ko) * 2000-06-21 2005-11-08 에프. 호프만-라 로슈 아게 벤조티아졸 유도체

Also Published As

Publication number Publication date
UY27551A1 (es) 2003-06-30
ES2303558T3 (es) 2008-08-16
AU2002352045B2 (en) 2006-08-17
AR037418A1 (es) 2004-11-10
JP4216193B2 (ja) 2009-01-28
GT200200240A (es) 2003-07-30
DE60226063D1 (en) 2008-05-21
PA8558201A1 (es) 2003-09-05
EP1450796A1 (en) 2004-09-01
EP1450796B1 (en) 2008-04-09
ATE391505T1 (de) 2008-04-15
CA2467825A1 (en) 2003-06-05
CN1325052C (zh) 2007-07-11
US6596718B1 (en) 2003-07-22
KR100613197B1 (ko) 2006-08-21
WO2003045385A1 (en) 2003-06-05
MXPA04004982A (es) 2004-08-11
JP2005526007A (ja) 2005-09-02
DE60226063T2 (de) 2009-05-20
TW200408391A (en) 2004-06-01
KR20040062968A (ko) 2004-07-09
BR0214455A (pt) 2004-11-03
AU2002352045A1 (en) 2003-06-10
CN1731999A (zh) 2006-02-08
RU2293083C2 (ru) 2007-02-10
PL370978A1 (en) 2005-06-13
RU2004119438A (ru) 2006-01-10

Similar Documents

Publication Publication Date Title
PE20030735A1 (es) Derivados de benzotiazol
PE20020104A1 (es) Derivados de benzotiazol
FR18C1006I1 (fr) Derives de quinoline ayant un groupe azolyle et derives de quinazoline
PE20020593A1 (es) Activadores de glucocinasa del tipo isoindolin-2-ona
MXPA04006003A (es) Derivados del acido fenilpropionico substituidos como agonistas al receptor alfa activado-proliferativo de peroxisoma (ppar) humano.
BR9910621A (pt) Novos compostos de imidazol 2-alquil substituìdos
PE20030761A1 (es) Derivados del 7-amino-benzotiazol
AR033753A1 (es) Derivados de imidazo[1,5-a]pirimido[5,4-d]benzazepina
ATE157966T1 (de) 22-oxacholecalziferol-derivate und ihre herstellung
ATE280767T1 (de) Antidiabetische thiazolidindione und ihre herstellung
AR041481A1 (es) Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
DE3072187D1 (de) Mittel zur regulierung des pflanzenwachstums, deren herstellung und deren verwendung.
KR970006302A (ko) 4-아미노-3-아실나프티리딘 유도체
AR003924A1 (es) Bencensulfonilureas y bencensulfoniltioureas sustituidas, procedimiento para su preparacion, empleo de las mismas y agente curativo que las contiene
AR021094A1 (es) Compuestos heterociclicos inhibidores de la fosfodiesterasa iv y su uso para el tratamiento de enfermedades inflamatorias
ATE23328T1 (de) 2-amino-1,2,3,4-tetrahydronaphthalen-derivate, ihre herstellung und ihre therapeutische verwendung.
ES2039364T3 (es) Derivados de n - ariltetrahidroftalimida y sus productos previos.
HUP9701134A2 (hu) Új kumarinszármazékok, eljárás előállításukra és intermedierként való alkalmazásuk új gyógyhatású kumarinszármazékok előállítására
ES528877A0 (es) Procedimiento de preparacion de derivados del biciclo (4.2.0.) 1,3,5-octatrieno
BR0116721A (pt) Processo para a preparação de (±)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperi dina
DE69205685D1 (de) 2-aminonaphthyridin-derivat, seine herstellung und verwendung.
DE69002340D1 (de) Pyrimidin-derivate, 2-(4-(alpha-heteroaryl-alpha-aryl-(alpha-alkyl)-methoxy)-butyl)-1-piperazinyl) mit serotoninergischer wirkung.
MX9100345A (es) Procedimiento para la preparacion de derivados 6-(aminopropionil sustituidos)de forscolina
PE20010382A1 (es) Forma cristalina iii de la n-(4-(5-dimetilaminonaftalen-1-sulfonilamino)fenil)-3-hidroxi-2,2-dimetilpropionamida
UY29306A1 (es) Procedimiento para preparar derivados de glicósido de tiofeno

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed